ALKS up +0.93% percent Today $ALKS High is at 53.6
Post# of 97
Posted On: 11/11/2014 3:47:01 PM
ALKS up +0.93% percent Today $ALKS High is at 53.60 and the Low 52.07 with current volume of 449,404.
Recent News posted below.
Alkermes Plc ALKS other info.
http://investorshangout.com/Alkermes-ALKS-53277/
ALKS Alkermes Plc Recent Headline News
Post Earnings Update: Alkermes Has Climbed 2.8% Higher in Past Week (ALKS)
Comtex SmarTrend(R) - Mon Nov 10, 1:12PM CST
When Alkermes (NASDAQ:ALKS) reported earnings a week ago on October 29th, 2014, analysts, on average, expected the company to report earnings of $0.02 on sales of $155.6 million. Alkermes actually reported earnings of $0.03 per share on sales of $160.0 million, beating EPS estimates by $0.01 and beating revenue estimates by $4.4 million. Since the company's report, shares of Alkermes have risen from $49.61 to $51.00, representing a gain of 2.8% in the past 12 days.
ALKS: 52.62 (-0.02)
Major Depressive Disorder Therapeutics in Major Developed Markets to 2020
M2 - Mon Nov 10, 10:10AM CST
Research and Markets (http://www.researchandmarkets.com/research/pwsnhg/major_depressive) has announced the addition of the "Major Depressive Disorder Therapeutics in Major Developed Markets to 2020" report to their offering. The global market for Major Depressive Disorder (MDD) therapeutics was valued at $8.7 billion in 2013, and several key patent expiries will cause it to decline at a negative Compound Annual Growth Rate (CAGR) of 4% to $7.4 billion by 2017. The decline is due to key patent expiries of blockbuster drugs such as Lexapro, Cymbalta, Abilify, and Seroquel XR during the forecast period. The expected launch of few promising pipeline molecules such as brexpiprazole, cariprazine, ALKS-5461, GLYX-13 is likely to offset the key patent expiries. Recently launched Brintellix which has a novel multimodal mechanism of action and is the only drug which can provide improvements in cognitive function is expected to lead the market by the end of forecasting period. New drug launches after 2017 will reinvigorate the market, which will increase at a CAGR of 3.5% to $8.1 billion by 2020 Scope: - A brief introduction to MDD, including the disease's pathophysiology, etiology, diagnosis and treatment algorithms. - In-depth analysis of currently marketed drugs for MDD, including analysis of their safety, efficacy, treatment patterns and strengths/weaknesses. Including a heat map comparing the drugs in terms of safety and efficacy - A comprehensive review of the pipeline for MDD, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market during the forecast period. The pipeline is analyzed on the basis of phase distribution, molecule types, program types, mechanisms of action and molecular targets - Additional in-depth analysis of pipeline drug clinical trials by phase, trial size, trial duration and program failure rate for each molecule type. - Multi-scenario forecast data of the market to 2020, taking into account how the market may be affected by the introduction of new drugs, the expiry of key patents on current drugs and the changes in disease epidemiology across the key developed markets. - Discussion of the drivers and barriers for market growth. - In-depth analysis of all licensing and co-development deals that have occurred in the MDD market since 2006. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Marketed Products Therapeutic Landscape - Lexapro/Cipralex (escitalopram) - Lundbeck/Forest Laboratories - Viibryd (vilazodone) - Forest (Actavis) - Cymbalta (duloxetine) - Eli Lilly - Pristiq (desvenlafaxine) - Pfizer - Seroquel XR (quetiapine) - AstraZeneca - Brintellix (vortioxetine) - Takeda and Lundbeck - Abilify (aripiprazole) - Otsuka Comparative Efficacy and Safety 4 Major Depressive Disorder Market to 2020 - Pipeline Products Overall Pipeline Pipeline Analysis by Molecule Type Pipeline Analysis by Mechanism of Action Clinical Trials - Failure Rate - Patient Enrollment and Clinical Trial Size - Duration Promising Drug Candidates in the Pipeline - OPC-34712 (brexpiprazole) - Otsuka and Lundbeck - ALKS-5461 - Alkermes - Amitifadine (EB-1010) - Euthymics Bioscience 5 Market Forecast to 2020 Geographical Markets Drivers and Barriers 6 Deals and Strategic Consolidations Major Licensing Deals - Ranbaxy Pharma Enters into Licensing Agreement with Alembic Pharma for desvenlafaxine Base Extended-Release Tablets - Forest Labs Enters into Licensing Agreement with Moksha8 for Viibryd - AstraZeneca Enters into Collaboration and Licensing Agreement with Targacept - Impax Labs Enters into Licensing Agreement with Wyeth Major Co-development Deals - Lundbeck Enters into Co-Development Agreement with Otsuka Pharma - Azaya Lundbeck Enters into Co-Development Agreement with Takeda 7 Appendix For more information visit http://www.researchandmarkets.com/research/pw...depressive
LLY: 67.96 (-0.39), ALKS: 52.62 (-0.02)
Technical Pulse on Biotech Stocks - Dendreon, Alkermes, Exact Sciences, Inovio Pharma, and Seattle Genetics
PR Newswire - Mon Nov 10, 8:05AM CST
Investor-Edge has initiated coverage on the following equities: Dendreon Corporation (NASDAQ: DNDN), Alkermes PLC (NASDAQ: ALKS), Exact Sciences Corporation (NASDAQ: EXAS), Inovio Pharmaceuticals Inc. (NASDAQ: INO), and Seattle Genetics Inc. (NASDAQ: SGEN). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Friday, November 07, 2014, ended on a mixed note as the Dow Jones Industrial Average finished at 17,573.93, up 0.11% and the NASDAQ Composite closed at 4,632.53, down 0.13%. The S&P 500 finished the session 0.03% higher at 2,031.92. During the trading session, seven out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 775.27, down 0.94%, whereas the index has gained 10.75% in the previous three months. Register for your complimentary reports on these five stocks at:
INO: 11.35 (+0.11), SGEN: 36.75 (-0.15), DNDN: 0.15 (-0.03), EXAS: 22.45 (-0.15), ALKS: 52.62 (-0.02)
Alkermes Up 15.8% Since SmarTrend Uptrend Call (ALKS)
Comtex SmarTrend(R) - Wed Nov 05, 9:32AM CST
SmarTrend identified an Uptrend for Alkermes (NASDAQ:ALKS) on October 21st, 2014 at $43.66. In approximately 2 weeks, Alkermes has returned 15.76% as of today's recent price of $50.54.
ALKS: 52.62 (-0.02)
Alkermes' Corporate Presentation to be Webcast at the Credit Suisse 2014 Healthcare Conference
Business Wire - Tue Nov 04, 3:00PM CST
Alkermes plc (NASDAQ: ALKS) announced today that its corporate presentation will be webcast live at the Credit Suisse 2014 Healthcare Conference on Tuesday, Nov. 11, 2014, at 11:00 a.m. MST (1:00 p.m. EST/6:00 p.m. GMT) from Phoenix, Ariz. The presentation may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.
ALKS: 52.62 (-0.02)
Alkermes Incurs Wider Q3 Loss but Revenues Grow Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 3:30PM CDT
Alkermes' (ALKS) third-quarter 2014 loss came in at 25 cents per share, much wider than the loss of 5 cents reported in the year-ago quarter.
BIIB: 323.07 (-4.80), AZN: 74.16 (+0.95), ACOR: 35.74 (-0.50), ALKS: 52.62 (-0.02)
Alkermes' (ALKS) CEO Rich Pops on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Oct 29, 2:11PM CDT
ALKS: 52.62 (-0.02)
Alkermes affirms guidance after Q3 results
Seeking Alpha - at Seeking Alpha - Wed Oct 29, 11:51AM CDT
ALKS: 52.62 (-0.02)
Alkermes reports 3Q loss
Automated Insights - Wed Oct 29, 9:07AM CDT
DUBLIN 4, Ireland (AP) _ Alkermes PLC (ALKS) on Wednesday reported a loss of $40 million in its third quarter.
ALKS: 52.62 (-0.02)
Alkermes (ALKS) Q2 2015 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Wed Oct 29, 7:25AM CDT
ALKS: 52.62 (-0.02)
Alkermes beats by $0.01, beats on revenue
Seeking Alpha - at Seeking Alpha - Wed Oct 29, 6:13AM CDT
ALKS: 52.62 (-0.02)
Alkermes plc Reports Third Quarter 2014 Financial Results
Business Wire - Wed Oct 29, 6:00AM CDT
---- Non-GAAP Diluted EPS of $0.03 for Third Quarter --
ALKS: 52.62 (-0.02)
Notable earnings before Wednesday’s open
Seeking Alpha - at Seeking Alpha - Tue Oct 28, 4:30PM CDT
AUO: 4.66 (-0.18), PSXP: 66.46 (-0.98), GHM: 33.08 (-0.90), CTCM: 6.15 (-0.04), HSY: 96.47 (-0.11), RYAM: 25.09 (-1.09), AIT: 49.51 (+0.11), AMED: 25.05 (-0.09), MRGE: 3.03 (-0.15), RL: 171.09 (-0.83), JLL: 141.72 (+1.70), CFR: 80.70 (-0.74), SPW: 92.90 (+0.17), CKSW: 7.38 (-0.06), IACI: 65.56 (-0.35), DXYN: 7.60 (+0.06), ROL: 32.50 (+0.03), NVMI: 10.69 (-0.06), PSX: 73.47 (-1.03), ETN: 68.42 (-0.96), RES: 15.79 (+0.08), HES: 83.85 (+0.04), EXC: 37.56 (-0.04), COT: 6.43 (-0.10), SEE: 38.21 (-0.54), VLY: 9.97 (-0.03), MHFI: 89.37 (-1.23), WLP: 126.64 (+1.14), UAM: 8.84 (-0.01), ADP: 84.83 (-0.29), PX: 126.48 (+0.11), STM: 6.92 (+0.04), CCJ: 19.64 (+0.44), ALLY: 22.75 (-0.03), GRMN: 55.73 (+0.15), SPWR: 29.26 (-1.14), PAG: 47.35 (+0.25), H: 58.50 (+1.10), WEC: 49.63 (-0.13), ARW: 57.82 (+0.26), CMC: 16.69 (-0.02), BDC: 71.93 (+0.02), TEL: 61.58 (+0.08), ACCO: 8.63 (-0.22), AVX: 14.05 (-0.01), LFUS: 97.49 (-0.40), BAH: 26.05 (+0.19), UBSI: 35.53 (-0.11), ALKS: 52.62 (-0.02), SO: 47.52 (-0.07), WM: 49.35 (-0.14), EVER: 18.96 (-0.06), ISSI: 13.86 (-0.05), GT: 25.25 (-0.08), SKYW: 12.34 (-0.02), TFX: 114.46 (+0.33), SODA: 21.61 (-0.14), MTH: 38.64 (+1.40), OMG: 26.97 (-0.32), PB: 60.45 (-0.23)
Watch for Alkermes to Potentially Pullback After Gaining 1.96% Yesterday
Comtex SmarTrend(R) - Wed Oct 22, 5:35PM CDT
Alkermes (NASDAQ:ALKS) traded in a range yesterday that spanned from a low of $43.38 to a high of $44.79. Yesterday, the shares gained 2.0%, which took the trading range above the 3-day high of $44.18 on volume of 703,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ALKS: 52.62 (-0.02)
Alkermes reports October 29
Seeking Alpha - at Seeking Alpha - Wed Oct 22, 4:45PM CDT
ALKS: 52.62 (-0.02)
Alkermes to Host Conference Call to Discuss Third Quarter 2014 Financial Results
Business Wire - Wed Oct 22, 3:00PM CDT
Alkermes plc (NASDAQ: ALKS) will host a conference call at 8:30 a.m. EDT (12:30 p.m. GMT) on Wednesday, Oct. 29, 2014, to discuss the company's financial results for the third quarter of 2014. Management will review the quarter and provide an update on the company.
ALKS: 52.62 (-0.02)
FDA to review Alkermes' NDA for antipsychotic med
Seeking Alpha - at Seeking Alpha - Wed Oct 22, 9:43AM CDT
ALKS: 52.62 (-0.02)
Alkermes' New Drug Application for Aripiprazole Lauroxil for Treatment of Schizophrenia Accepted for Filing by U.S. FDA
Business Wire - Wed Oct 22, 6:00AM CDT
---- FDA Action Expected by Aug. 22, 2015 --
ALKS: 52.62 (-0.02)
OTC Daily Alert Stock Watch - Alkermes Public Limited Company (NASDAQ: ALKS)
WorldStockWire - Sat Oct 18, 11:45PM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
ALKS: 52.62 (-0.02)
FDA clears Pfizer's abuse deterrent pain med
Seeking Alpha - at Seeking Alpha - Fri Oct 17, 4:20PM CDT
MNK: 93.11 (-0.12), EGLT: 6.55 (-0.19), ZGNX: 1.34 (+0.03), PFE: 30.22 (+0.02), TEVA: 58.24 (+0.20), ABBV: 63.65 (-0.14), ALKS: 52.62 (-0.02), ACUR: 0.56 (-0.01)
Recent News posted below.
Alkermes Plc ALKS other info.
http://investorshangout.com/Alkermes-ALKS-53277/
ALKS Alkermes Plc Recent Headline News
Post Earnings Update: Alkermes Has Climbed 2.8% Higher in Past Week (ALKS)
Comtex SmarTrend(R) - Mon Nov 10, 1:12PM CST
When Alkermes (NASDAQ:ALKS) reported earnings a week ago on October 29th, 2014, analysts, on average, expected the company to report earnings of $0.02 on sales of $155.6 million. Alkermes actually reported earnings of $0.03 per share on sales of $160.0 million, beating EPS estimates by $0.01 and beating revenue estimates by $4.4 million. Since the company's report, shares of Alkermes have risen from $49.61 to $51.00, representing a gain of 2.8% in the past 12 days.
ALKS: 52.62 (-0.02)
Major Depressive Disorder Therapeutics in Major Developed Markets to 2020
M2 - Mon Nov 10, 10:10AM CST
Research and Markets (http://www.researchandmarkets.com/research/pwsnhg/major_depressive) has announced the addition of the "Major Depressive Disorder Therapeutics in Major Developed Markets to 2020" report to their offering. The global market for Major Depressive Disorder (MDD) therapeutics was valued at $8.7 billion in 2013, and several key patent expiries will cause it to decline at a negative Compound Annual Growth Rate (CAGR) of 4% to $7.4 billion by 2017. The decline is due to key patent expiries of blockbuster drugs such as Lexapro, Cymbalta, Abilify, and Seroquel XR during the forecast period. The expected launch of few promising pipeline molecules such as brexpiprazole, cariprazine, ALKS-5461, GLYX-13 is likely to offset the key patent expiries. Recently launched Brintellix which has a novel multimodal mechanism of action and is the only drug which can provide improvements in cognitive function is expected to lead the market by the end of forecasting period. New drug launches after 2017 will reinvigorate the market, which will increase at a CAGR of 3.5% to $8.1 billion by 2020 Scope: - A brief introduction to MDD, including the disease's pathophysiology, etiology, diagnosis and treatment algorithms. - In-depth analysis of currently marketed drugs for MDD, including analysis of their safety, efficacy, treatment patterns and strengths/weaknesses. Including a heat map comparing the drugs in terms of safety and efficacy - A comprehensive review of the pipeline for MDD, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market during the forecast period. The pipeline is analyzed on the basis of phase distribution, molecule types, program types, mechanisms of action and molecular targets - Additional in-depth analysis of pipeline drug clinical trials by phase, trial size, trial duration and program failure rate for each molecule type. - Multi-scenario forecast data of the market to 2020, taking into account how the market may be affected by the introduction of new drugs, the expiry of key patents on current drugs and the changes in disease epidemiology across the key developed markets. - Discussion of the drivers and barriers for market growth. - In-depth analysis of all licensing and co-development deals that have occurred in the MDD market since 2006. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Marketed Products Therapeutic Landscape - Lexapro/Cipralex (escitalopram) - Lundbeck/Forest Laboratories - Viibryd (vilazodone) - Forest (Actavis) - Cymbalta (duloxetine) - Eli Lilly - Pristiq (desvenlafaxine) - Pfizer - Seroquel XR (quetiapine) - AstraZeneca - Brintellix (vortioxetine) - Takeda and Lundbeck - Abilify (aripiprazole) - Otsuka Comparative Efficacy and Safety 4 Major Depressive Disorder Market to 2020 - Pipeline Products Overall Pipeline Pipeline Analysis by Molecule Type Pipeline Analysis by Mechanism of Action Clinical Trials - Failure Rate - Patient Enrollment and Clinical Trial Size - Duration Promising Drug Candidates in the Pipeline - OPC-34712 (brexpiprazole) - Otsuka and Lundbeck - ALKS-5461 - Alkermes - Amitifadine (EB-1010) - Euthymics Bioscience 5 Market Forecast to 2020 Geographical Markets Drivers and Barriers 6 Deals and Strategic Consolidations Major Licensing Deals - Ranbaxy Pharma Enters into Licensing Agreement with Alembic Pharma for desvenlafaxine Base Extended-Release Tablets - Forest Labs Enters into Licensing Agreement with Moksha8 for Viibryd - AstraZeneca Enters into Collaboration and Licensing Agreement with Targacept - Impax Labs Enters into Licensing Agreement with Wyeth Major Co-development Deals - Lundbeck Enters into Co-Development Agreement with Otsuka Pharma - Azaya Lundbeck Enters into Co-Development Agreement with Takeda 7 Appendix For more information visit http://www.researchandmarkets.com/research/pw...depressive
LLY: 67.96 (-0.39), ALKS: 52.62 (-0.02)
Technical Pulse on Biotech Stocks - Dendreon, Alkermes, Exact Sciences, Inovio Pharma, and Seattle Genetics
PR Newswire - Mon Nov 10, 8:05AM CST
Investor-Edge has initiated coverage on the following equities: Dendreon Corporation (NASDAQ: DNDN), Alkermes PLC (NASDAQ: ALKS), Exact Sciences Corporation (NASDAQ: EXAS), Inovio Pharmaceuticals Inc. (NASDAQ: INO), and Seattle Genetics Inc. (NASDAQ: SGEN). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Friday, November 07, 2014, ended on a mixed note as the Dow Jones Industrial Average finished at 17,573.93, up 0.11% and the NASDAQ Composite closed at 4,632.53, down 0.13%. The S&P 500 finished the session 0.03% higher at 2,031.92. During the trading session, seven out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 775.27, down 0.94%, whereas the index has gained 10.75% in the previous three months. Register for your complimentary reports on these five stocks at:
INO: 11.35 (+0.11), SGEN: 36.75 (-0.15), DNDN: 0.15 (-0.03), EXAS: 22.45 (-0.15), ALKS: 52.62 (-0.02)
Alkermes Up 15.8% Since SmarTrend Uptrend Call (ALKS)
Comtex SmarTrend(R) - Wed Nov 05, 9:32AM CST
SmarTrend identified an Uptrend for Alkermes (NASDAQ:ALKS) on October 21st, 2014 at $43.66. In approximately 2 weeks, Alkermes has returned 15.76% as of today's recent price of $50.54.
ALKS: 52.62 (-0.02)
Alkermes' Corporate Presentation to be Webcast at the Credit Suisse 2014 Healthcare Conference
Business Wire - Tue Nov 04, 3:00PM CST
Alkermes plc (NASDAQ: ALKS) announced today that its corporate presentation will be webcast live at the Credit Suisse 2014 Healthcare Conference on Tuesday, Nov. 11, 2014, at 11:00 a.m. MST (1:00 p.m. EST/6:00 p.m. GMT) from Phoenix, Ariz. The presentation may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.
ALKS: 52.62 (-0.02)
Alkermes Incurs Wider Q3 Loss but Revenues Grow Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 3:30PM CDT
Alkermes' (ALKS) third-quarter 2014 loss came in at 25 cents per share, much wider than the loss of 5 cents reported in the year-ago quarter.
BIIB: 323.07 (-4.80), AZN: 74.16 (+0.95), ACOR: 35.74 (-0.50), ALKS: 52.62 (-0.02)
Alkermes' (ALKS) CEO Rich Pops on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Oct 29, 2:11PM CDT
ALKS: 52.62 (-0.02)
Alkermes affirms guidance after Q3 results
Seeking Alpha - at Seeking Alpha - Wed Oct 29, 11:51AM CDT
ALKS: 52.62 (-0.02)
Alkermes reports 3Q loss
Automated Insights - Wed Oct 29, 9:07AM CDT
DUBLIN 4, Ireland (AP) _ Alkermes PLC (ALKS) on Wednesday reported a loss of $40 million in its third quarter.
ALKS: 52.62 (-0.02)
Alkermes (ALKS) Q2 2015 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Wed Oct 29, 7:25AM CDT
ALKS: 52.62 (-0.02)
Alkermes beats by $0.01, beats on revenue
Seeking Alpha - at Seeking Alpha - Wed Oct 29, 6:13AM CDT
ALKS: 52.62 (-0.02)
Alkermes plc Reports Third Quarter 2014 Financial Results
Business Wire - Wed Oct 29, 6:00AM CDT
---- Non-GAAP Diluted EPS of $0.03 for Third Quarter --
ALKS: 52.62 (-0.02)
Notable earnings before Wednesday’s open
Seeking Alpha - at Seeking Alpha - Tue Oct 28, 4:30PM CDT
AUO: 4.66 (-0.18), PSXP: 66.46 (-0.98), GHM: 33.08 (-0.90), CTCM: 6.15 (-0.04), HSY: 96.47 (-0.11), RYAM: 25.09 (-1.09), AIT: 49.51 (+0.11), AMED: 25.05 (-0.09), MRGE: 3.03 (-0.15), RL: 171.09 (-0.83), JLL: 141.72 (+1.70), CFR: 80.70 (-0.74), SPW: 92.90 (+0.17), CKSW: 7.38 (-0.06), IACI: 65.56 (-0.35), DXYN: 7.60 (+0.06), ROL: 32.50 (+0.03), NVMI: 10.69 (-0.06), PSX: 73.47 (-1.03), ETN: 68.42 (-0.96), RES: 15.79 (+0.08), HES: 83.85 (+0.04), EXC: 37.56 (-0.04), COT: 6.43 (-0.10), SEE: 38.21 (-0.54), VLY: 9.97 (-0.03), MHFI: 89.37 (-1.23), WLP: 126.64 (+1.14), UAM: 8.84 (-0.01), ADP: 84.83 (-0.29), PX: 126.48 (+0.11), STM: 6.92 (+0.04), CCJ: 19.64 (+0.44), ALLY: 22.75 (-0.03), GRMN: 55.73 (+0.15), SPWR: 29.26 (-1.14), PAG: 47.35 (+0.25), H: 58.50 (+1.10), WEC: 49.63 (-0.13), ARW: 57.82 (+0.26), CMC: 16.69 (-0.02), BDC: 71.93 (+0.02), TEL: 61.58 (+0.08), ACCO: 8.63 (-0.22), AVX: 14.05 (-0.01), LFUS: 97.49 (-0.40), BAH: 26.05 (+0.19), UBSI: 35.53 (-0.11), ALKS: 52.62 (-0.02), SO: 47.52 (-0.07), WM: 49.35 (-0.14), EVER: 18.96 (-0.06), ISSI: 13.86 (-0.05), GT: 25.25 (-0.08), SKYW: 12.34 (-0.02), TFX: 114.46 (+0.33), SODA: 21.61 (-0.14), MTH: 38.64 (+1.40), OMG: 26.97 (-0.32), PB: 60.45 (-0.23)
Watch for Alkermes to Potentially Pullback After Gaining 1.96% Yesterday
Comtex SmarTrend(R) - Wed Oct 22, 5:35PM CDT
Alkermes (NASDAQ:ALKS) traded in a range yesterday that spanned from a low of $43.38 to a high of $44.79. Yesterday, the shares gained 2.0%, which took the trading range above the 3-day high of $44.18 on volume of 703,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ALKS: 52.62 (-0.02)
Alkermes reports October 29
Seeking Alpha - at Seeking Alpha - Wed Oct 22, 4:45PM CDT
ALKS: 52.62 (-0.02)
Alkermes to Host Conference Call to Discuss Third Quarter 2014 Financial Results
Business Wire - Wed Oct 22, 3:00PM CDT
Alkermes plc (NASDAQ: ALKS) will host a conference call at 8:30 a.m. EDT (12:30 p.m. GMT) on Wednesday, Oct. 29, 2014, to discuss the company's financial results for the third quarter of 2014. Management will review the quarter and provide an update on the company.
ALKS: 52.62 (-0.02)
FDA to review Alkermes' NDA for antipsychotic med
Seeking Alpha - at Seeking Alpha - Wed Oct 22, 9:43AM CDT
ALKS: 52.62 (-0.02)
Alkermes' New Drug Application for Aripiprazole Lauroxil for Treatment of Schizophrenia Accepted for Filing by U.S. FDA
Business Wire - Wed Oct 22, 6:00AM CDT
---- FDA Action Expected by Aug. 22, 2015 --
ALKS: 52.62 (-0.02)
OTC Daily Alert Stock Watch - Alkermes Public Limited Company (NASDAQ: ALKS)
WorldStockWire - Sat Oct 18, 11:45PM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
ALKS: 52.62 (-0.02)
FDA clears Pfizer's abuse deterrent pain med
Seeking Alpha - at Seeking Alpha - Fri Oct 17, 4:20PM CDT
MNK: 93.11 (-0.12), EGLT: 6.55 (-0.19), ZGNX: 1.34 (+0.03), PFE: 30.22 (+0.02), TEVA: 58.24 (+0.20), ABBV: 63.65 (-0.14), ALKS: 52.62 (-0.02), ACUR: 0.56 (-0.01)
(0)
(0)Alkermes plc (ALKS) Stock Research Links
Scroll down for more posts ▼